President Trump has made much, in public, of his zeal for lowering the “out of control” drug prices in the U.S. market. Choosing former Eli Lilly top exec Alex Azar to replace the disgraced Tom Price as Secretary of Health and Human Services will all but guarantee that doesn’t happen.
Before he was named Trump’s health secretary, Price took a congressional trip to Australia and pressed officials to extend protections for drug companies in an international trade agreement.
In the spring before the 2016 presidential election, the Obama administration's 12-nation trade agreement known as the Trans-Pacific Partnership, or TPP, was still alive. Negotiators worked on details as Congress considered whether to ratify the pact. The Australian government was getting in the way of one change demanded by U.S. pharmaceutical